Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis

Oncologist

Volumn 21, Issue 7, 2016, Pages 848-854

  Kuk, Deborah ^a   Shoushtari, Alexander N ^a,b   Barker, Christopher A ^a   Panageas, Katherine S ^a   Munhoz, Rodrigo R ^a   Momtaz, Parisa ^a,b   Ariyan, Charlotte E ^a   Brady, Mary Sue ^a   Coit, Daniel G ^a   Bogatch, Kita ^a   Callahan, Margaret K ^a,b   Wolchok, Jedd D ^a,b   Carvajal, Richard D ^c   Postow, Michael A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Acral cutaneous melanoma; Mucosal melanoma; Nonacral cutaneous melanoma; Prognosis; Unknown primary melanoma; Uveal melanoma

Indexed keywords

B RAF KINASE INHIBITOR; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TRAMETINIB;

ACRAL MELANOMA; ADULT; AGED; ARTICLE; CUTANEOUS MELANOMA; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUCOSAL MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UVEA MELANOMA; ADOLESCENT; CANCER OF UNKNOWN PRIMARY SITE; CHILD; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; PROGNOSIS; SECONDARY; SKIN TUMOR; UVEA TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 84978473836     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0522     Document Type: Article

References (38)

1. McLaughlin CC,Wu XC, Jemal A et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005;103: 1000-1007.
2. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. Cancer 1998;83: 1664-1678.
3. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353: 2135-2147.
4. Curtin JA, Busam K, Pinkel D et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24: 4340-4346.
5. Van Raamsdonk CD, Griewank KG, Crosby MB et al. Mutations inGNA11in uvealmelanoma. NEngl JMed 2010; 363: 2191-2199.
6. Bae JM, Choi YY, Kim DS et al. Metastatic melanomas of unknown primary show better prognosis than those of known primary: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2015;72: 59-70.
7. Egberts F, Bergner I, Kruger S et al. Metastatic melanomaofunknownprimaryresemblesthegenotype of cutaneous melanomas. AnnOncol 2014; 25: 246-250.
8. Gos A, Jurkowska M, van Akkooi A et al. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. Ann Surg Oncol 2014;21: 4317-4323.
9. Bachar G, Loh KS, O’Sullivan B et al. Mucosal melanomas of the head and neck: Experience of the Princess Margaret Hospital. Head Neck 2008;30: 1325-1331.
10. Frumovitz M, Etchepareborda M, Sun CC et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010;116: 1358-1365.
11. Kim HS, Kim EK, Jun HJ et al. Noncutaneous malignant melanoma: A prognostic model from a retrospective multicenter study. BMC Cancer 2010; 10: 167.
12. Onken MD, Worley LA, Ehlers JP et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64: 7205-7209.
13. BelloDM,Chou JF, Panageas KS et al. Prognosis of acral melanoma: A series of 281 patients. Ann Surg Oncol 2013;20: 3618-3625.
14. Mehra T, Grözinger G, Mann S et al. Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma. PLoS One 2014;9: e112535.
15. Sanlorenzo M, Ribero S, Osella-Abate S et al. Prognostic differences across sexes in melanoma patients: What has changed from the past? Melanoma Res 2014;24: 568-576.
16. Joosse A, Collette S, Suciu S et al. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: A pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol 2013;31: 2337-2346.
17. Schlagenhauff B, StroebelW, EllwangerUet al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: Recommendations for initial staging examinations. Cancer 1997;80: 60-65.
18. Lee CC, Faries MB,Wanek LA et al. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009;27: 3489-3495.
19. Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: A retrospective matched cohort study. Ann Oncol 1998;9: 419-422.
20. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastaticmelanoma. NEngl JMed 2010;363: 711-723.
21. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
22. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl JMed 2011;364: 2507-2516.
23. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380: 358-365.
24. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl JMed 2012;367: 107-114.
25. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl JMed 2015;372: 2521-2532.
26. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372: 320-330.
27. Luke JJ, Callahan MK, Postow MA et al. Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013;119: 3687-3695.
28. Danielli R, Ridolfi R, Chiarion-Sileni V et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: Safety and clinical efficacy. Cancer Immunol Immunother 2012;61: 41-48.
29. Maio M, Danielli R, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013;24: 2911-2915.
30. Carvajal RD, Sosman JA, Quevedo JF et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial. JAMA 2014;311: 2397-2405.
31. Rietschel P, Panageas KS, Hanlon C et al. Variates of survival in metastatic uvealmelanoma. J Clin Oncol 2005;23: 8076-8080.
32. Gragoudas ES, Egan KM, Seddon JM et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98: 383-390.
33. Diener-West M, Reynolds SM, Agugliaro DJ et al. Screening for metastasis from choroidal melanoma: The Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 2004;22: 2438-2444.
34. Valpione S, Moser JC, Parrozzani R et al. Development and external validation of a prognostic nomogram formetastatic uvealmelanoma. PLoS One 2015;10: e0120181.
35. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27: 6199-6206.
36. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013;500: 415-421.
37. Hodis E, Watson IR, Kryukov GV et al. A landscape of driver mutations in melanoma. Cell 2012;150: 251-263.
38. Furney SJ, Turajlic S, Stamp G et al. Genome sequencing of mucosal melanomasreveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 2013;230: 261-269.